Japan Cytomegalovirus (CMV) Infection Market Insights, Epidemiology and Market Forecast 2013-2023 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast - 2023 - Japan" drug pipelines to their offering.

Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast - 2023 - Japan

This report provides an overview of the disease and market size of the CMV for Japan. It also includes historical and forecasted epidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infant Patients at High Risk of CMV and HIV Patients at High Risk of CMV from 2013 - 2023.

According to experts, the total number of Diagnosed Cytomegalovirus (CMV) Infection cases is expected to increase at a CAGR of 0.056% to 7,355 cases in 2023. Out of all these high-risk categories, Infants have a comparatively higher number of CMV prevalent cases than HIV and Transplant patients in Japan. The market size for Cytomegalovirus (CMV) Infection shall reach to USD 68.1 Million by the end of 2023.

Scope:

  • Report covers the disease overview, including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
  • Marketed information, including available prescription drugs.
  • The Report also covers the detailed historical and forecasted epidemiological data covering Japan from 2013 - 2023.
  • It also provides market size of Cytomegalovirus (CMV) infection for Japan from 2013 and forecasted market size to 2023.

Key Topics Covered:

  1. Cytomegalovirus Infections
  2. Disease Overview
  3. Symptoms of Cytomegalovirus (CMV) Infection
  4. Etiology
  5. Risk Factors
  6. Pathogenesis of Human Cytomegalovirus
  7. Pathophysiology of Cytomegalovirus Infection
  8. Diagnosis
  9. Treatment Algorithm for Cytomegalovirus Infections
  10. Treatment for Congenital CMV Infection
  11. Treatment of Ganciclovir-Resistant CMV
  12. Treatment Guidelines
  13. Recommendations for Treating Cytomegalovirus Infections
  14. Disease Management
  15. Epidemiology and Patient Population
  16. Assumptions and Rationale
  17. Total CMV Prevalent, Diagnosed and Treatable Cases
  18. CMV Patients Among Transplants
  19. Infant Patients at High Risk of CMV
  20. HIV Patients at High Risk of CMV in Japan
  21. Unmet Medical Needs

Marketed Products

  • Valcyte (Valganciclovir hydrochloride)
  • FOSCAVIR (foscarnet sodium)
  • CytoGam (Cytomegalovirus Immune Globulin Intravenous-Human)
  • CytoTect CP
  • Valtrex (Valacyclovir hydrochloride)

Approved Products

  • Cytovir CMV: Cell Medica Ltd.

Pipeline Products (Phase III)

  • CytoTect CP 70: Biotest AG
  • Letermovir: Merck & Co.
  • Brincidofovir: Chimerix Inc.
  • ASP0113: Astellas Pharma Global Development, Inc.
  • Human Cytomegalovirus Immune Globulin: CSL Behring

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/447ph8/cytomegalovirus.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs